Contrasting OPKO Health (NASDAQ:OPK) & Super Nova Resources (OTCMKTS:SNRR)

Super Nova Resources (OTCMKTS:SNRR) and OPKO Health (NASDAQ:OPK) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, risk, institutional ownership, dividends, profitability, valuation and analyst recommendations.

Profitability

This table compares Super Nova Resources and OPKO Health’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Super Nova Resources	N/A	N/A	N/A
OPKO Health	-12.40%	-5.88%	-3.83%

Valuation and Earnings

This table compares Super Nova Resources and OPKO Health”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Super Nova Resources	N/A	N/A	N/A	N/A	N/A
OPKO Health	$606.90 million	1.62	-$225.68 million	($0.09)	-14.67

Super Nova Resources has higher earnings, but lower revenue than OPKO Health.

Insider and Institutional Ownership

64.6% of OPKO Health shares are owned by institutional investors. 17.6% of Super Nova Resources shares are owned by insiders. Comparatively, 44.7% of OPKO Health shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Super Nova Resources and OPKO Health, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Super Nova Resources	0	0	0	0	0.00
OPKO Health	1	4	1	0	2.00

OPKO Health has a consensus price target of $1.55, indicating a potential upside of 17.42%. Given OPKO Health’s stronger consensus rating and higher probable upside, analysts clearly believe OPKO Health is more favorable than Super Nova Resources.

Volatility and Risk

Super Nova Resources has a beta of -0.57, indicating that its stock price is 157% less volatile than the S&P 500. Comparatively, OPKO Health has a beta of 1.48, indicating that its stock price is 48% more volatile than the S&P 500.

Summary

OPKO Health beats Super Nova Resources on 7 of the 10 factors compared between the two stocks.

About Super Nova Resources

Super Nova Resources, Inc. provides employment screening and talent management software as a service. The company's employment screening services include assessment tests, background checks, drug and alcohol testing, and Form I-9 compliance. Its integrated talent management software suite consists of three modules for applicant tracking, onboarding, and performance management. The company's clients principally operate in markets, such as healthcare, staffing, transportation-logistics, and retail-hospitality. It delivers its services to approximately 1,000 clients in the United States. Super Nova Resources, through its division, Greenlink Interactive, also provides sales and marketing services to partner companies for a range of industries, venues, and customer types via its interactive technologies and distribution channels. The company develops business models for various sectors, products, and services, including home improvement products, wellness, apparel, real estate, housing, and gifts. It utilizes specialized marketing techniques in conjunction with proprietary Greenlink Interactive Video Assistance, Always-On, and Point-of-Decision Systems to market and sell products and services. In addition, Super Nova Resources has a joint venture agreement with Early Detect, Inc. to develop Live Interactive Point-of-Decision Systems to be deployed in retail locations. The company was formerly known as Navicus, Inc. and changed its name to Super Nova Resources, Inc. in November 2008. Super Nova Resources, Inc. was incorporated in 1965 and is based in Corona, California.

About OPKO Health

OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test. Its Pharmaceutical segment offers Rayaldee to treat secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency. This segment also develops multi-specific immune therapies focused on oncology, infectious diseases, vaccines, and immunology; OPK88004, an orally administered selective androgen receptor modulator; OPK88003, a once-weekly administered peptide for the treatment of type 2 diabetes and related obesity; Somatrogon (hGH-CTP), a once-weekly human growth hormone injection; and Factor VIIa-CTP, a novel long-acting coagulation factor being developed to treat hemophilia. In addition, it develops and commercializes longer-acting proprietary versions of already approved therapeutic proteins; develops and produces specialty APIs; develops, manufactures, markets, and sells pharmaceutical, nutraceutical, veterinary, and ophthalmic products; commercializes food supplements and over the counter products; manufactures and sells products primarily in the generics market; and markets, distributes, and sells pharmaceutical products in a range of indications, including cardiovascular products, vaccines, antibiotics, gastro-intestinal products, hormones, and others. The company also operates pharmaceutical platforms in Ireland, Chile, Spain, and Mexico. The company was founded in 1991 and is headquartered in Miami, Florida.